<DOC>
	<DOCNO>NCT00841048</DOCNO>
	<brief_summary>The primary aim study investigate safety tolerability AZD4017 give multiple oral ascending dose healthy volunteer . This do comparing effect AZD4017 placebo . The study aslo investigate absorption , distribution disappearance AZD4017 body . Information plasma concentration AZD4017 v time dose intake also collect measure pharmacokinetics versus pharmacodynamics include . The future indication AZD4017 plan Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Phase I Study Healthy Volunteers Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics AZD4017 After Repeated Ascending Oral Doses</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Provision sign write date informed consent BMI 19 30 kg/m2 Subjects must willing use barrier method contraception History clinically significant disease Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration investigational product History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug Laboratory blood sample result show elevate liver enzyme ( ASAT , ALAT ) muscle enzyme ( CK ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Safety tolerability</keyword>
</DOC>